查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1882973

麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測 (2024-2032)

Measles, Mumps, Rubella (MMR) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場成長驅動因子

由於傳染病流行率的上升、全球疫苗接種活動的擴大以及主要衛生組織的大力支持，全球麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場正在快速擴張。根據本報告，市場規模預計將在 2024 年成長至 50.6 億美元，2025 年將成長至 51.7 億美元，到 2032 年將達到 110.1 億美元，預測期內複合年增長率 (CAGR) 為 11.4%。 2024年，北美將佔最大的市場佔有率，達到37.15%，這得益於其健全的公共衛生體系和高疫苗接種率。

麻疹、腮腺炎、德國麻疹 (MMR) 疫苗使用減毒活病毒誘發免疫，預防三種高傳染性病毒性疾病：麻疹、腮腺炎和德國麻疹。這些疫苗通常在兒童12個月和4歲時接種兩次，已證實具有很高的有效性。根據美國疾病管制與預防中心 (CDC) 2025年1月發布的數據，MMR疫苗第一劑對麻疹的有效率為93%，對腮腺炎的有效率為72%，對德國麻疹的有效率為97%，這支持了其在全球的推廣應用。葛蘭素史克 (GSK plc)、印度血清研究所 (Serum Institute of India Pvt. Ltd.) 等疫苗生產商加強了研發力道。有限公司和默克公司正在進一步加速市場發展。

市場動態

驅動因素

政府主導的免疫規劃是全球麻疹、腮腺炎、德國麻疹 (MMR) 疫苗需求的主要驅動因素。美國和印度等國家已將 MMR 疫苗納入國家免疫規劃，確保符合條件的兒童能夠廣泛接種。世界衛生組織 (WHO) 和全球疫苗免疫聯盟 (Gavi) 等國際組織正透過提供資金和後勤支援來加強這些工作。例如，Gavi 在 2025 年 5 月報告稱，在將 MR 疫苗納入常規免疫規劃之前，他們支持了多個國家的麻疹-德國麻疹後續疫苗接種活動。

抑制因子

疫苗猶豫仍是市場成長的最大障礙之一。錯誤訊息、對副作用的誤解以及對醫療保健系統的不信任等因素都會降低疫苗的接受度。根據美國國家生物技術資訊中心 (NCBI) 2023 年 10 月發布的報告，許多家長因擔心發燒和注射部位疼痛而避免給孩子接種麻疹、腮腺炎、德國麻疹 (MMR) 疫苗，這表明感知風險對疫苗接種率的影響。

機會

微陣列貼片 (MAP) 等技術創新為開發無針頭、耐熱且易於接種的 MMR 疫苗提供了巨大潛力。這些技術創新有助於提高疫苗接種依從性，尤其是在醫療資源有限的低收入地區。 2019 年，聯合國兒童基金會和世界衛生組織開始與合作夥伴共同開發微陣列貼片，這代表著未來廣泛應用的一條充滿希望​​的途徑。

挑戰

保持冷鏈完整性是一項持續的挑戰。 MMR 疫苗對溫度波動高度敏感，處理不當會降低疫苗效力並增加浪費。美國疾病管制與預防中心基金會 (CDC Foundation) 2024 年 9 月的報告證實，麻疹疫苗極容易受到溫度波動的影響，凸顯了許多地區冷鏈的限制。

市場趨勢

影響麻疹、腮腺炎、德國麻疹 (MMR) 疫苗市場的一個關鍵趨勢是，旨在彌補免疫接種缺口的公私合作模式的興起。這些合作加強了疫苗分發，改善了疫苗物流，並促進了社區參與。根據全球疫苗免疫聯盟 (Gavi) 2025 年 5 月發布的數據，2013 年至 2017 年間，該聯盟向麻疹和風疹倡議撥款 5,500 萬美元，這表明其對疾病控製做出了長期的財務承諾。

細分市場分析

按類型

2024 年，聯合疫苗細分市場佔主導地位，因為它具有方便、經濟高效以及只需一次注射即可預防三種疾病的優點。 2022年6月，葛蘭素史克(GSK)的Priorix獲得FDA批准，進一步鞏固了該細分市場的成長。

依產品劃分

2024年，麻疹-腮腺炎-德國麻疹二聯疫苗(MMR II)引領市場，這得益於其在美國30年來超過2.31億劑的銷售記錄，證明了其在全球範圍內長期且可靠的應用。由於獲得了廣泛的監管批准和強有力的臨床證據，PRIORIX預計將快速成長。

依給藥途徑劃分

2024年，皮下注射佔最大市佔率。這是因為大多數麻疹-腮腺炎-德國麻疹疫苗，包括MMR II和PRIORIX，都獲準皮下注射。

依年齡組別劃分

由於兒童對麻疹、腮腺炎、德國麻疹 (MMR) 疫苗的高易感性以及該疫苗已深度納入兒童免疫接種計劃，預計 2024 年兒科市場將佔最大佔有率。

依通路劃分

由於各國免疫規劃的大規模採購，政府供應商佔了市場主導地位。 2021 年，聯合國兒童基金會代表 35 個國家採購了 1.81 億劑 MMR 疫苗。

區域展望

預計 2024 年，北美市場規模將達到 18.8 億美元，這得益於其強大的免疫基礎設施和公共衛生舉措。美國憑藉全面的疫苗接種政策和持續的疾病監測，在該地區處於領先地位。由於歐盟/歐洲經濟區國家強制接種兩劑疫苗，歐洲也維持較高的市場佔有率。亞太地區是成長最快的地區，這主要得益於各國疫苗接種計劃的擴展以及透過諸如印度全民免疫計劃（UIP）等舉措實施的免費疫苗接種。拉丁美洲以及中東和非洲地區也呈現穩定成長，這得益於人們免疫意識的提高和醫療保健服務的改善。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家/地區主要疾病的發生率/盛行率（2024 年）
  • 主要公司產品線分析
  • 主要國家疫苗接種覆蓋率概述
  • 麻疹、腮腺炎、德國麻疹 (MMR) 疫苗的技術進步
  • 主要公司新產品發布
  • 主要產業趨勢，包括併購和合作夥伴關係

第五章：全球麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 按類型劃分
    • 單價疫苗
    • 聯合疫苗
  • 市場分析、洞察與預測 - 按產品劃分
    • MMR II
    • PRIORIX
    • MMR Pro
    • Tresivac
    • 其他
  • 市場分析、洞察與預測 - 按給藥途徑劃分
    • 肌肉注
    • 皮下注射
    • 其他
  • 市場分析、洞察與預測 - 按年齡劃分組別
    • 兒科
    • 成人
  • 市場分析、洞察與預測 - 按分銷管道劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東與非洲麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • 葛蘭素史克 (GSK) plc.
    • 印度血清研究所私人有限公司
    • 默克公司
    • 印度免疫學有限公司
    • Zydus生命科學股份有限公司
    • 武田藥品工業株式會社
    • BIOLOGICAL E. LIMITED
    • Invivyd公司
    • 第一三共株式會社
Product Code: FBI113753

Growth Factors of measles, mumps, rubella (MMR) vaccines Market

The global measles, mumps, rubella (MMR) vaccines market is expanding rapidly due to rising infectious disease prevalence, increasing global immunization efforts, and strong support from major health organizations. According to the report, the market size was USD 5.06 billion in 2024, is expected to increase to USD 5.17 billion in 2025, and reach USD 11.01 billion by 2032, exhibiting a CAGR of 11.4% during the forecast period. In 2024, North America held the largest share at 37.15%, driven by robust public health systems and high vaccination coverage.

MMR vaccines protect against three highly contagious viral diseases-measles, mumps, and rubella-using weakened live viruses to induce immunity. Administered in two doses, typically at 12 months and again at 4 years of age, these vaccines demonstrate strong effectiveness. CDC data published in January 2025 shows the first MMR dose is 93% effective against measles, 72% effective against mumps, and 97% effective against rubella, supporting their continued global adoption. Increasing R&D activities by vaccine manufacturers such as GSK plc., Serum Institute of India Pvt. Ltd., and Merck & Co., Inc. further accelerate market progress.

Market Dynamics

Drivers

Government-backed immunization programs are a major driver of global MMR vaccine demand. Countries such as the U.S. and India have integrated MMR into national immunization schedules, ensuring widespread availability for eligible children. Global organizations, including WHO and Gavi, amplify these efforts through financial and logistical support. For example, in May 2025, Gavi reported supporting measles-rubella catch-up campaigns in multiple countries before MR vaccines were added to routine immunization.

Restraints

Vaccine hesitancy remains one of the most significant barriers to market growth. Factors such as misinformation, misconceptions about side effects, and distrust in healthcare systems reduce vaccine acceptance. According to an October 2023 publication by the National Center for Biotechnology Information, many parents avoided MMR vaccination due to concerns about fever and injection-site pain, demonstrating the influence of perceived risks on uptake.

Opportunities

Technological advancements such as microarray patches (MAPs) create significant opportunities for needle-free, thermostable, and easy-to-administer MMR vaccines. These innovations improve compliance, especially in low-income regions with limited healthcare access. UNICEF and WHO began developing microarray patches in collaboration with partners in 2019, offering a strong pathway for future adoption.

Challenges

Maintaining cold chain integrity presents an ongoing challenge. MMR vaccines are extremely sensitive to temperature fluctuations, and improper handling can reduce efficacy and increase wastage. A September 2024 CDC Foundation report confirmed the measles vaccine's high vulnerability to temperature variations, highlighting cold-chain limitations in many regions.

Market Trends

A key trend shaping the MMR vaccine market is the rise in public-private partnerships aimed at addressing immunization gaps. These collaborations enhance distribution, improve vaccine logistics, and strengthen community engagement. Gavi data published in May 2025 showed that USD 55 million was allocated to the Measles & Rubella Initiative between 2013 and 2017, demonstrating long-term financial commitment to disease control.

Segmentation Insights

By Type

The combination vaccine segment dominated in 2024 due to its convenience, cost-effectiveness, and ability to protect against all three diseases through a single injection. FDA approval of GSK's Priorix in June 2022 further strengthened segment growth.

By Product

M-M-R II led the market in 2024, supported by more than 231 million doses sold in the U.S. over 30 years, indicating long-proven global usage. PRIORIX is expected to grow rapidly due to its wide regulatory approvals and strong clinical evidence.

By Route of Administration

The subcutaneous route accounted for the largest share in 2024, as most MMR vaccines-including M-M-R II and PRIORIX-are approved for SC administration.

By Age Group

The pediatric segment held the highest share in 2024 due to heightened susceptibility of children and strong inclusion of MMR in childhood immunization schedules.

By Distribution Channel

Government suppliers dominated due to large-scale procurement for national immunization programs. UNICEF procured 181 million MR vaccine doses in 2021 on behalf of 35 countries.

Regional Outlook

In 2024, North America generated USD 1.88 billion, driven by strong vaccination infrastructure and public health initiatives. The U.S. leads the region with comprehensive immunization policies and continuous disease monitoring. Europe holds a strong share due to mandatory two-dose schedules across EU/EEA countries. Asia Pacific is the fastest-growing region due to expansions of national immunization programs and free vaccine administration under initiatives such as India's Universal Immunization Programme (UIP). Latin America and Middle East & Africa show steady growth supported by rising awareness and improving healthcare access.

Conclusion

Expanding from USD 5.06 billion in 2024 to USD 11.01 billion by 2032, the MMR vaccines market is set for strong growth through improved awareness, technological innovation, public-private collaborations, and strengthened immunization programs worldwide.

Segmentation By Type

  • Standalone
  • Combination

By Product

  • M-M-R II
  • PRIORIX
  • M-M-RvaxPro
  • Tresivac
  • Others

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Others

By Age Group

  • Adult
  • Pediatric

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Overview: Immunization Coverage, By Key Countries
  • 4.4. Technological Advancements in the MMR Vaccines
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Standalone
    • 5.1.2. Combination
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. M-M-R II
    • 5.2.2. PRIORIX
    • 5.2.3. M-M-RvaxPro
    • 5.2.4. Tresivac
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Intramuscular
    • 5.3.2. Subcutaneous
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatrics
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Standalone
    • 6.1.2. Combination
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. M-M-R II
    • 6.2.2. PRIORIX
    • 6.2.3. M-M-RvaxPro
    • 6.2.4. Tresivac
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Intramuscular
    • 6.3.2. Subcutaneous
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatrics
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Standalone
    • 7.1.2. Combination
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. M-M-R II
    • 7.2.2. PRIORIX
    • 7.2.3. M-M-RvaxPro
    • 7.2.4. Tresivac
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Intramuscular
    • 7.3.2. Subcutaneous
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatrics
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Standalone
    • 8.1.2. Combination
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. M-M-R II
    • 8.2.2. PRIORIX
    • 8.2.3. M-M-RvaxPro
    • 8.2.4. Tresivac
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Intramuscular
    • 8.3.2. Subcutaneous
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatrics
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Standalone
    • 9.1.2. Combination
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. M-M-R II
    • 9.2.2. PRIORIX
    • 9.2.3. M-M-RvaxPro
    • 9.2.4. Tresivac
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Intramuscular
    • 9.3.2. Subcutaneous
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatrics
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Standalone
    • 10.1.2. Combination
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. M-M-R II
    • 10.2.2. PRIORIX
    • 10.2.3. M-M-RvaxPro
    • 10.2.4. Tresivac
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Intramuscular
    • 10.3.2. Subcutaneous
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatrics
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Serum Institute of India Pvt. Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Indian Immunologicals Limited
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Lifesciences Limited
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Takeda Pharmaceutical Company Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BIOLOGICAL E. LIMITED
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Invivyd, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Daiichi Sankyo Company, Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 16: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 17: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 19: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 20: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 22: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 23: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 26: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 28: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 29: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 32: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 34: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 35: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024 & 2032
  • Figure 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 13: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 14: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 15: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 16: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country, 2024
  • Figure 20: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 21: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 22: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 25: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 26: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 27: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 28: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 33: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 34: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 37: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 38: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 39: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 40: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 45: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 46: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 49: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 50: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 51: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 52: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 57: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 58: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 61: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 62: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 63: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 64: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Measles, Mumps, Rubella (MMR) Vaccines Market Share (%), By Company, 2024